Products from BPS Bioscience require a minimum order value above 400€
Applications: Useful as CD19-expressing target cells in co-culture assay with CD19-CAR-T cells, for both CD19-specific cell killing assay and cytokine production assay.
Background: B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be used as a target for leukemia immunotherapies. CD19-targeted therapies based on T cells that express CD19-specific chimeric antigen receptors (CARs) have been utilized for their antitumor abilities in patients with CD19+ lymphoma and leukemia, such as Non-Hodgkins Lymphoma (NHL), CLL and ALL.
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD19 protein (also known as B4 or CVID3, Genbank #NM_001770) and the firefly luciferase. Surface expression of CD19 was confirmed by flow cytometry.
Host Cell Line: CHO
Mycoplasma Testing: This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.
Storage Stability: Store in liquid nitrogen immediately upon receipt.
Supplied As: Each vial contains ~2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Warnings: Avoid multiple freeze/thaw cycles.
Biosafety Level: BSL-1
References: Application References:1. Tedder TF, et al. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J. Immunol. 1989 Jul 15;143(2):7122. Kemeng W, et al. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Experimental Hematology & Oncology 2012 1:363. Michel S. CD19 CAR T Cells. Cell 2017 Dec 14; 171(7):1471